Journal of Biological Chemistry
Volume 295, Issue 52, 25 December 2020, Pages 18589-18603
Journal home page for Journal of Biological Chemistry

Molecular Biophysics
Molecular architecture and domain arrangement of the placental malaria protein VAR2CSA suggests a model for carbohydrate binding

https://doi.org/10.1074/jbc.RA120.014676Get rights and content
Under a Creative Commons license
open access

VAR2CSA is the placental-malaria–specific member of the antigenically variant Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family. It is expressed on the surface of Plasmodium falciparum-infected host red blood cells and binds to specific chondroitin-4-sulfate chains of the placental proteoglycan receptor. The functional ∼310 kDa ectodomain of VAR2CSA is a multidomain protein that requires a minimum 12-mer chondroitin-4-sulfate molecule for specific, high affinity receptor binding. However, it is not known how the individual domains are organized and interact to create the receptor-binding surface, limiting efforts to exploit its potential as an effective vaccine or drug target. Using small angle X-ray scattering and single particle reconstruction from negative-stained electron micrographs of the ectodomain and multidomain constructs, we have determined the structural architecture of VAR2CSA. The relative locations of the domains creates two distinct pores that can each accommodate the 12-mer of chondroitin-4-sulfate, suggesting a model for receptor binding. This model has important implications for understanding cytoadherence of infected red blood cells and potentially provides a starting point for developing novel strategies to prevent and/or treat placental malaria.

placental malaria
Plasmodium falciparum erythrocyte protein 1
VAR2CSA
chondroitin 4-sulfate
small angle x-ray scattering
electron microscopy
malaria
carbohydrate function
electron microscopy (EM)
protein structure
mass spectrometry
Plasmodium falciparum erythrocyte protein-1

Cited by (0)

This article contains supporting information.

Author contributions—M. C. B., D. C. G., and J. M. F. conceptualization; M. C. B. and J. M. F. resources; M. C. B., M. G. J., and J. M. F. data curation; M. C. B., L. G., M. G. J., D. C. G., and J. M. F. formal analysis; M. G. J. performed mass spectrometry experiments; M. C. B., D. C. G., and J. M. F. supervision; D. C. G. and J. M. F. funding acquisition; M. C. B. and J. M. F. validation; M. C. B., M. G. J., D. C. G., and J. M. F. investigation; M. C. B. and J. M. F. visualization; M. C. B., L. G., M. G. J., and J. M. F. methodology; M. C. B., D. C. G., and J. M. F. writing-original draft; M. C. B., L. G., M. G. J., D. C. G., and J. M. F. writing-review and editing; D. C. G. and J. M. F. project administration.

Funding and additional information—This work was supported by NIAID National Institutes of Health Grant R01 AI104844 (to D. C. G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are:

    Pf
    IRBC

    infected red blood cell

    CSA

    chondroitin-4-sulfate

    CSPG

    chondroitin sulfate proteoglycan

    PM

    placental malaria

    DBL

    Duffy binding-like

    ID

    interdomain

    SAXS

    small angle X-ray scattering

    HEK

    human embryonic kidney

    GAG

    glycosaminoglycans

    aa

    amino acid(s)

.

These authors contributed equally to this work.